These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169 [TBL] [Abstract][Full Text] [Related]
33. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221 [TBL] [Abstract][Full Text] [Related]
34. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Moss RB; Giermakowska W; Wallace MR; Savary J; Jensen F; Carlo DJ Clin Diagn Lab Immunol; 2000 Sep; 7(5):724-7. PubMed ID: 10973444 [TBL] [Abstract][Full Text] [Related]
35. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. Cobb A; Roberts LK; Palucka AK; Mead H; Montes M; Ranganathan R; Burkeholder S; Finholt JP; Blankenship D; King B; Sloan L; Harrod AC; Lévy Y; Banchereau J J Immunol Methods; 2011 Feb; 365(1-2):27-37. PubMed ID: 21093448 [TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911 [TBL] [Abstract][Full Text] [Related]
37. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822 [TBL] [Abstract][Full Text] [Related]
39. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512 [TBL] [Abstract][Full Text] [Related]
40. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells. Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]